Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 9985 to 9996 of 27694 entries
Sorted by: Best Match Show Resources per page
Which Out-of-Hospital Cardiac Arrest Patients without ST-Segment Elevation Benefit from Early Coronary Angiography? Results from the Korean Hypothermia Network Prospective Registry.

Journal of clinical medicine

Song H, Kim HJ, Park KN, Kim SH, Kim WY, Lee BK, Cho IS, Lee JH, Youn CS, On Behalf Of The Korean Hypothermia Network Investigators.
PMID: 33498728
J Clin Med. 2021 Jan 23;10(3). doi: 10.3390/jcm10030439.

The effect of early coronary angiography (CAG) in out-of-hospital cardiac arrest (OHCA) patients without ST-elevation (STE) is still controversial. It is not known which subgroups of patients without STE are the most likely to benefit. The objective of this...

Cite
Song H, Kim HJ, Park KN, et al. Which Out-of-Hospital Cardiac Arrest Patients without ST-Segment Elevation Benefit from Early Coronary Angiography? Results from the Korean Hypothermia Network Prospective Registry. J Clin Med. 2021;10(3)doi: 10.3390/jcm10030439.
Song, H., Kim, H. J., Park, K. N., Kim, S. H., Kim, W. Y., Lee, B. K., Cho, I. S., Lee, J. H., Youn, C. S., & On Behalf Of The Korean Hypothermia Network Investigators. (2021). Which Out-of-Hospital Cardiac Arrest Patients without ST-Segment Elevation Benefit from Early Coronary Angiography? Results from the Korean Hypothermia Network Prospective Registry. Journal of clinical medicine, 10(3), . https://doi.org/10.3390/jcm10030439
Song, Hwan, et al. "Which Out-of-Hospital Cardiac Arrest Patients without ST-Segment Elevation Benefit from Early Coronary Angiography? Results from the Korean Hypothermia Network Prospective Registry." Journal of clinical medicine vol. 10,3 (2021). doi: https://doi.org/10.3390/jcm10030439
Song H, Kim HJ, Park KN, Kim SH, Kim WY, Lee BK, Cho IS, Lee JH, Youn CS, On Behalf Of The Korean Hypothermia Network Investigators. Which Out-of-Hospital Cardiac Arrest Patients without ST-Segment Elevation Benefit from Early Coronary Angiography? Results from the Korean Hypothermia Network Prospective Registry. J Clin Med. 2021 Jan 23;10(3). doi: 10.3390/jcm10030439. PMID: 33498728; PMCID: PMC7865270.
Copy Download .nbib Format: NLM
New Circulating Circular RNAs with Diagnostic and Prognostic Potential in Advanced Colorectal Cancer.

International journal of molecular sciences

Radanova M, Mihaylova G, Tasinov O, Ivanova DP, Stoyanov GS, Nazifova-Tasinova N, Manev R, Salim A, Nikolova M, Ivanova DG, Conev N, Mihaylova Z, Donev I.
PMID: 34948079
Int J Mol Sci. 2021 Dec 10;22(24). doi: 10.3390/ijms222413283.

Circular RNAs (circRNAs) are a group of special endogenous long non-coding RNAs which are highly stable in the circulation, and, thus, more suitable as new biomarkers of colorectal cancer (CRC). The aim of our study was to explore the...

Cite
Radanova M, Mihaylova G, Tasinov O, et al. New Circulating Circular RNAs with Diagnostic and Prognostic Potential in Advanced Colorectal Cancer. Int J Mol Sci. 2021;22(24)doi: 10.3390/ijms222413283.
Radanova, M., Mihaylova, G., Tasinov, O., Ivanova, D. P., Stoyanov, G. S., Nazifova-Tasinova, N., Manev, R., Salim, A., Nikolova, M., Ivanova, D. G., Conev, N., Mihaylova, Z., & Donev, I. (2021). New Circulating Circular RNAs with Diagnostic and Prognostic Potential in Advanced Colorectal Cancer. International journal of molecular sciences, 22(24), . https://doi.org/10.3390/ijms222413283
Radanova, Maria, et al. "New Circulating Circular RNAs with Diagnostic and Prognostic Potential in Advanced Colorectal Cancer." International journal of molecular sciences vol. 22,24 (2021). doi: https://doi.org/10.3390/ijms222413283
Radanova M, Mihaylova G, Tasinov O, Ivanova DP, Stoyanov GS, Nazifova-Tasinova N, Manev R, Salim A, Nikolova M, Ivanova DG, Conev N, Mihaylova Z, Donev I. New Circulating Circular RNAs with Diagnostic and Prognostic Potential in Advanced Colorectal Cancer. Int J Mol Sci. 2021 Dec 10;22(24). doi: 10.3390/ijms222413283. PMID: 34948079; PMCID: PMC8706615.
Copy Download .nbib Format: NLM
Substance-P prevents the cholestatic liver injury by regulating inflammatory responses.

Peptides

Kim S, Hong HS.
PMID: 33440226
Peptides. 2021 Mar;137:170494. doi: 10.1016/j.peptides.2021.170494. Epub 2021 Jan 10.

Substance-P (SP) is a neuropeptide that modulates immune responses and accelerates tissue repair in critical inflammatory disease. Liver fibrosis and cirrhosis are the ultimate outcomes of almost all chronic liver diseases caused by viral infection, steatohepatitis, autoimmune, and cholestatic...

Cite
Kim S, Hong HS. Substance-P prevents the cholestatic liver injury by regulating inflammatory responses. Peptides. 2021;137:170494doi: 10.1016/j.peptides.2021.170494.
Kim, S., & Hong, H. S. (2021). Substance-P prevents the cholestatic liver injury by regulating inflammatory responses. Peptides, 137170494. https://doi.org/10.1016/j.peptides.2021.170494
Kim, Suna, and Hong, Hyun Sook. "Substance-P prevents the cholestatic liver injury by regulating inflammatory responses." Peptides vol. 137 (2021): 170494. doi: https://doi.org/10.1016/j.peptides.2021.170494
Kim S, Hong HS. Substance-P prevents the cholestatic liver injury by regulating inflammatory responses. Peptides. 2021 Mar;137:170494. doi: 10.1016/j.peptides.2021.170494. Epub 2021 Jan 10. PMID: 33440226.
Copy Download .nbib Format: NLM
Synthetic polymers as drug-delivery vehicles in medicine.

Metal-based drugs

Neuse EW.
PMID: 18497867
Met Based Drugs. 2008;2008:469531. doi: 10.1155/2008/469531.

Cancerous diseases present a formidable health problem worldwide. While the chemotherapy of cancer, in conjunction with other treatment modalities, has reached a significant level of maturity, efficacious use of such agents is still restricted by numerous pharmacological deficiencies, such...

Cite
Neuse EW. Synthetic polymers as drug-delivery vehicles in medicine. Met Based Drugs. 2008;2008:469531doi: 10.1155/2008/469531.
Neuse, E. W. (2008). Synthetic polymers as drug-delivery vehicles in medicine. Metal-based drugs, 2008469531. https://doi.org/10.1155/2008/469531
Neuse, Eberhard W. "Synthetic polymers as drug-delivery vehicles in medicine." Metal-based drugs vol. 2008 (2008): 469531. doi: https://doi.org/10.1155/2008/469531
Neuse EW. Synthetic polymers as drug-delivery vehicles in medicine. Met Based Drugs. 2008;2008:469531. doi: 10.1155/2008/469531. PMID: 18497867; PMCID: PMC2386871.
Copy Download .nbib Format: NLM
Heating Tobacco Sticks Instead of Combusting Conventional Cigarettes and Future Heart Attacks: Still Smoke, and Risk.

Circulation

Auer R, Diethelm P, Berthet A.
PMID: 34748392
Circulation. 2021 Nov 09;144(19):1539-1542. doi: 10.1161/CIRCULATIONAHA.121.056959. Epub 2021 Nov 08.

No abstract available.

Cite
Auer R, Diethelm P, Berthet A. Heating Tobacco Sticks Instead of Combusting Conventional Cigarettes and Future Heart Attacks: Still Smoke, and Risk. Circulation. 2021;144(19):1539-1542doi: 10.1161/CIRCULATIONAHA.121.056959.
Auer, R., Diethelm, P., & Berthet, A. (2021). Heating Tobacco Sticks Instead of Combusting Conventional Cigarettes and Future Heart Attacks: Still Smoke, and Risk. Circulation, 144(19), 1539-1542. https://doi.org/10.1161/CIRCULATIONAHA.121.056959
Auer, Reto, et al. "Heating Tobacco Sticks Instead of Combusting Conventional Cigarettes and Future Heart Attacks: Still Smoke, and Risk." Circulation vol. 144,19 (2021): 1539-1542. doi: https://doi.org/10.1161/CIRCULATIONAHA.121.056959
Auer R, Diethelm P, Berthet A. Heating Tobacco Sticks Instead of Combusting Conventional Cigarettes and Future Heart Attacks: Still Smoke, and Risk. Circulation. 2021 Nov 09;144(19):1539-1542. doi: 10.1161/CIRCULATIONAHA.121.056959. Epub 2021 Nov 08. PMID: 34748392.
Copy Download .nbib Format: NLM
Colchicine in Patients With Acute Coronary Syndrome: Two-Year Follow-Up of the Australian COPS Randomized Clinical Trial.

Circulation

Tong DC, Bloom JE, Quinn S, Nasis A, Hiew C, Roberts-Thomson P, Adams H, Sriamareswaran R, Htun NM, Wilson W, Stub D, van Gaal W, Howes L, Yeap A, Yip B, Wu S, Perera P, Collins N, Yong A, Bhindi R, Whitbourn R, Lee A, Premaratne M, Asrress K, Freeman M, Amerena J, Layland J.
PMID: 34748393
Circulation. 2021 Nov 09;144(19):1584-1586. doi: 10.1161/CIRCULATIONAHA.121.054610. Epub 2021 Nov 08.

No abstract available.

Cite
Tong DC, Bloom JE, Quinn S, et al. Colchicine in Patients With Acute Coronary Syndrome: Two-Year Follow-Up of the Australian COPS Randomized Clinical Trial. Circulation. 2021;144(19):1584-1586doi: 10.1161/CIRCULATIONAHA.121.054610.
Tong, D. C., Bloom, J. E., Quinn, S., Nasis, A., Hiew, C., Roberts-Thomson, P., Adams, H., Sriamareswaran, R., Htun, N. M., Wilson, W., Stub, D., van Gaal, W., Howes, L., Yeap, A., Yip, B., Wu, S., Perera, P., Collins, N., Yong, A., Bhindi, R., Whitbourn, R., Lee, A., Premaratne, M., Asrress, K., Freeman, M., Amerena, J., & Layland, J. (2021). Colchicine in Patients With Acute Coronary Syndrome: Two-Year Follow-Up of the Australian COPS Randomized Clinical Trial. Circulation, 144(19), 1584-1586. https://doi.org/10.1161/CIRCULATIONAHA.121.054610
Tong, David C, et al. "Colchicine in Patients With Acute Coronary Syndrome: Two-Year Follow-Up of the Australian COPS Randomized Clinical Trial." Circulation vol. 144,19 (2021): 1584-1586. doi: https://doi.org/10.1161/CIRCULATIONAHA.121.054610
Tong DC, Bloom JE, Quinn S, Nasis A, Hiew C, Roberts-Thomson P, Adams H, Sriamareswaran R, Htun NM, Wilson W, Stub D, van Gaal W, Howes L, Yeap A, Yip B, Wu S, Perera P, Collins N, Yong A, Bhindi R, Whitbourn R, Lee A, Premaratne M, Asrress K, Freeman M, Amerena J, Layland J. Colchicine in Patients With Acute Coronary Syndrome: Two-Year Follow-Up of the Australian COPS Randomized Clinical Trial. Circulation. 2021 Nov 09;144(19):1584-1586. doi: 10.1161/CIRCULATIONAHA.121.054610. Epub 2021 Nov 08. PMID: 34748393.
Copy Download .nbib Format: NLM
Toward CRISPR Therapies for Cardiomyopathies.

Circulation

Nishiyama T, Bassel-Duby R, Olson EN.
PMID: 34748394
Circulation. 2021 Nov 09;144(19):1525-1527. doi: 10.1161/CIRCULATIONAHA.121.057203. Epub 2021 Nov 08.

No abstract available.

Cite
Nishiyama T, Bassel-Duby R, Olson EN. Toward CRISPR Therapies for Cardiomyopathies. Circulation. 2021;144(19):1525-1527doi: 10.1161/CIRCULATIONAHA.121.057203.
Nishiyama, T., Bassel-Duby, R., & Olson, E. N. (2021). Toward CRISPR Therapies for Cardiomyopathies. Circulation, 144(19), 1525-1527. https://doi.org/10.1161/CIRCULATIONAHA.121.057203
Nishiyama, Takahiko, et al. "Toward CRISPR Therapies for Cardiomyopathies." Circulation vol. 144,19 (2021): 1525-1527. doi: https://doi.org/10.1161/CIRCULATIONAHA.121.057203
Nishiyama T, Bassel-Duby R, Olson EN. Toward CRISPR Therapies for Cardiomyopathies. Circulation. 2021 Nov 09;144(19):1525-1527. doi: 10.1161/CIRCULATIONAHA.121.057203. Epub 2021 Nov 08. PMID: 34748394; PMCID: PMC8580229.
Copy Download .nbib Format: NLM
Letter by Schaefer et al Regarding Article, "Diagnostic Performance of High-Sensitivity Cardiac Troponin T Strategies and Clinical Variables in a Multisite US Cohort".

Circulation

Schaefer I, Lopez-Ayala P, Mueller C.
PMID: 34748396
Circulation. 2021 Nov 09;144(19):e283-e284. doi: 10.1161/CIRCULATIONAHA.121.055719. Epub 2021 Nov 08.

No abstract available.

Cite
Schaefer I, Lopez-Ayala P, Mueller C. Letter by Schaefer et al Regarding Article, "Diagnostic Performance of High-Sensitivity Cardiac Troponin T Strategies and Clinical Variables in a Multisite US Cohort". Circulation. 2021;144(19):e283-e284doi: 10.1161/CIRCULATIONAHA.121.055719.
Schaefer, I., Lopez-Ayala, P., & Mueller, C. (2021). Letter by Schaefer et al Regarding Article, "Diagnostic Performance of High-Sensitivity Cardiac Troponin T Strategies and Clinical Variables in a Multisite US Cohort". Circulation, 144(19), e283-e284. https://doi.org/10.1161/CIRCULATIONAHA.121.055719
Schaefer, Ibrahim, et al. "Letter by Schaefer et al Regarding Article, "Diagnostic Performance of High-Sensitivity Cardiac Troponin T Strategies and Clinical Variables in a Multisite US Cohort"." Circulation vol. 144,19 (2021): e283-e284. doi: https://doi.org/10.1161/CIRCULATIONAHA.121.055719
Schaefer I, Lopez-Ayala P, Mueller C. Letter by Schaefer et al Regarding Article, "Diagnostic Performance of High-Sensitivity Cardiac Troponin T Strategies and Clinical Variables in a Multisite US Cohort". Circulation. 2021 Nov 09;144(19):e283-e284. doi: 10.1161/CIRCULATIONAHA.121.055719. Epub 2021 Nov 08. PMID: 34748396.
Copy Download .nbib Format: NLM
Artificial Nanoscale Erythrocytes from Clinically Relevant Compounds for Enhancing Cancer Immunotherapy.

Nano-micro letters

Ou W, Nam KS, Park DH, Hwang J, Ku SK, Yong CS, Kim JO, Byeon JH.
PMID: 34138119
Nanomicro Lett. 2020 Apr 13;12(1):90. doi: 10.1007/s40820-020-00428-y.

Because of enhanced efficacy and lower side effects, cancer immunotherapies have recently been extensively investigated in clinical trials to overcome the limitations of conventional cancer monotherapies. Although engineering attempts have been made to build nanosystems even including stimulus nanomaterials...

Cite
Ou W, Nam KS, Park DH, et al. Artificial Nanoscale Erythrocytes from Clinically Relevant Compounds for Enhancing Cancer Immunotherapy. Nanomicro Lett. 2020;12(1):90doi: 10.1007/s40820-020-00428-y.
Ou, W., Nam, K. S., Park, D. H., Hwang, J., Ku, S. K., Yong, C. S., Kim, J. O., & Byeon, J. H. (2020). Artificial Nanoscale Erythrocytes from Clinically Relevant Compounds for Enhancing Cancer Immunotherapy. Nano-micro letters, 12(1), 90. https://doi.org/10.1007/s40820-020-00428-y
Ou, Wenquan, et al. "Artificial Nanoscale Erythrocytes from Clinically Relevant Compounds for Enhancing Cancer Immunotherapy." Nano-micro letters vol. 12,1 (2020): 90. doi: https://doi.org/10.1007/s40820-020-00428-y
Ou W, Nam KS, Park DH, Hwang J, Ku SK, Yong CS, Kim JO, Byeon JH. Artificial Nanoscale Erythrocytes from Clinically Relevant Compounds for Enhancing Cancer Immunotherapy. Nanomicro Lett. 2020 Apr 13;12(1):90. doi: 10.1007/s40820-020-00428-y. PMID: 34138119; PMCID: PMC7770689.
Copy Download .nbib Format: NLM
A clinical and echocardiographic case report of carcinoid-related valvular heart disease.

European heart journal. Case reports

Ebrahimi AJ, Marogil P, Von Mering G, Ahmed M.
PMID: 33442593
Eur Heart J Case Rep. 2020 Nov 06;4(6):1-4. doi: 10.1093/ehjcr/ytaa363. eCollection 2020 Dec.

BACKGROUND: Carcinoid syndrome is a rare disease caused by malignant neuroendocrine neoplasms. When vasoactive substances enter the systemic circulation, the triad of cutaneous flushing, bronchospasm, and diarrhoea often characterize carcinoid syndrome. Rarely, carcinoid syndrome can progress to involve the...

Cite
Ebrahimi AJ, Marogil P, Von Mering G, et al. A clinical and echocardiographic case report of carcinoid-related valvular heart disease. Eur Heart J Case Rep. 2020;4(6):1-4doi: 10.1093/ehjcr/ytaa363.
Ebrahimi, A. J., Marogil, P., Von Mering, G., & Ahmed, M. (2020). A clinical and echocardiographic case report of carcinoid-related valvular heart disease. European heart journal. Case reports, 4(6), 1-4. https://doi.org/10.1093/ehjcr/ytaa363
Ebrahimi, Ali J, et al. "A clinical and echocardiographic case report of carcinoid-related valvular heart disease." European heart journal. Case reports vol. 4,6 (2020): 1-4. doi: https://doi.org/10.1093/ehjcr/ytaa363
Ebrahimi AJ, Marogil P, Von Mering G, Ahmed M. A clinical and echocardiographic case report of carcinoid-related valvular heart disease. Eur Heart J Case Rep. 2020 Nov 06;4(6):1-4. doi: 10.1093/ehjcr/ytaa363. eCollection 2020 Dec. PMID: 33442593; PMCID: PMC7793036.
Copy Download .nbib Format: NLM
Endovascular middle cerebral artery embolic stroke model: a novel approach.

Journal of neurointerventional surgery

Gonzalez LF, Warner DS, Sheng H, Chaparro E.
PMID: 34140285
J Neurointerv Surg. 2021 Jun 17; doi: 10.1136/neurintsurg-2021-017370. Epub 2021 Jun 17.

A video (video 1) describing a novel murine endovascular embolic stroke model is presented. Traditional middle cerebral artery (MCA) occlusion models include a blind insertion of a monofilament string12 into the common or external carotid artery with the expectation...

Cite
Gonzalez LF, Warner DS, Sheng H, et al. Endovascular middle cerebral artery embolic stroke model: a novel approach. J Neurointerv Surg. 2021;doi: 10.1136/neurintsurg-2021-017370.
Gonzalez, L. F., Warner, D. S., Sheng, H., & Chaparro, E. (2021). Endovascular middle cerebral artery embolic stroke model: a novel approach. Journal of neurointerventional surgery, . https://doi.org/10.1136/neurintsurg-2021-017370
Gonzalez, L Fernando, et al. "Endovascular middle cerebral artery embolic stroke model: a novel approach." Journal of neurointerventional surgery vol. (2021). doi: https://doi.org/10.1136/neurintsurg-2021-017370
Gonzalez LF, Warner DS, Sheng H, Chaparro E. Endovascular middle cerebral artery embolic stroke model: a novel approach. J Neurointerv Surg. 2021 Jun 17; doi: 10.1136/neurintsurg-2021-017370. Epub 2021 Jun 17. PMID: 34140285.
Copy Download .nbib Format: NLM
Identifying of Anti-Thrombin Active Components From Curcumae Rhizoma by Affinity-Ultrafiltration Coupled With UPLC-Q-Exactive Orbitrap/MS.

Frontiers in pharmacology

Lan Z, Zhang Y, Sun Y, Wang L, Huang Y, Cao H, Wang S, Meng J.
PMID: 34955839
Front Pharmacol. 2021 Dec 10;12:769021. doi: 10.3389/fphar.2021.769021. eCollection 2021.

Recent studies concerning products that originate from natural plants have sought to clarify active ingredients, which both explains the mechanisms of the function and aids in quality control during production. As a traditional functional plant, Curcumae Rhizoma (CR) has...

Cite
Lan Z, Zhang Y, Sun Y, et al. Identifying of Anti-Thrombin Active Components From Curcumae Rhizoma by Affinity-Ultrafiltration Coupled With UPLC-Q-Exactive Orbitrap/MS. Front Pharmacol. 2021;12:769021doi: 10.3389/fphar.2021.769021.
Lan, Z., Zhang, Y., Sun, Y., Wang, L., Huang, Y., Cao, H., Wang, S., & Meng, J. (2021). Identifying of Anti-Thrombin Active Components From Curcumae Rhizoma by Affinity-Ultrafiltration Coupled With UPLC-Q-Exactive Orbitrap/MS. Frontiers in pharmacology, 12769021. https://doi.org/10.3389/fphar.2021.769021
Lan, Zhenwei, et al. "Identifying of Anti-Thrombin Active Components From Curcumae Rhizoma by Affinity-Ultrafiltration Coupled With UPLC-Q-Exactive Orbitrap/MS." Frontiers in pharmacology vol. 12 (2021): 769021. doi: https://doi.org/10.3389/fphar.2021.769021
Lan Z, Zhang Y, Sun Y, Wang L, Huang Y, Cao H, Wang S, Meng J. Identifying of Anti-Thrombin Active Components From Curcumae Rhizoma by Affinity-Ultrafiltration Coupled With UPLC-Q-Exactive Orbitrap/MS. Front Pharmacol. 2021 Dec 10;12:769021. doi: 10.3389/fphar.2021.769021. eCollection 2021. PMID: 34955839; PMCID: PMC8703108.
Copy Download .nbib Format: NLM
Showing 9985 to 9996 of 27694 entries